Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Upstart Holdings Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Upstart Holdings Inc trades at $31.8 (market cap $3.04B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.6× Upstart Holdings Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BIO | UPST | |
|---|---|---|
Market Cap | $8.04B | $3.04B |
Sector | Health | Financials |
52-Week High | $339.75 | $84.13 |
52-Week Low | $241.71 | $24.22 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
UPST trades at $31.46, down 3.91% on the day, reflecting recent volatility amid mixed earnings. The stock shows a bearish technical trend with support near $29, while fundamentals highlight a return to profitability in 2025 with $1.02B revenue and $53.60M net income. Recent news emphasizes AI lending growth and a key $600M funding deal with Neuberger Berman, though margin pressures persist.
The outlook hinges on execution of AI-driven lending expansion and funding stability, with a consensus price target of $42.00 suggesting 33% upside. Risks include earnings volatility, high debt levels, and competitive fintech pressures. Analyst sentiment is balanced with 45% buy ratings, but investors await Q2 2026 results on August 4 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
